[{"from": "human", "value": "Provide a brief overview of this molecule. [C][O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][=C][Branch2][Ring1][=N][C][C][N][Branch1][Branch1][C][Ring1][=Branch1][=O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][C][C][C][C][Ring1][=Branch1][=O][C][=Branch1][Branch1][=N][Ring2][Ring1][#Branch1][C][=Branch1][C][=O][N]"}, {"from": "gpt", "value": "The molecule is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012."}]